Table 1.

Percentages of BrdU-labeled cells immunoreactive for calbindin, TOAD-64, or GFAP in the dentate gyrus of adult female rats at 4, 7, 14, and 21 d after BrdU injection

Days	Calbindin		TOAD-64		GFAP
	gcl and sgz	Hilus	gcl and sgz	Hilus	gcl and sgz	Hilus
4	2.5  ± 1.84%	None	60.4  ± 6.53%	None	14.8  ± 2.19%	<1.0%
7	10.3  ± 3.51%	None	73.1  ± 2.02%	None	13.8  ± 2.44%	<1.0%
14	34.2  ± 8.17%	None	53.3  ± 9.43%	None	17.0  ± 2.61%	<1.0%
21	68.3  ± 12.05%	None	51.8  ± 12.89%	None	22.6  ± 3.94%	<1.0%

The percentage of BrdU-labeled cells that were immunoreactive for calbindin, TOAD-64, or GFAP in all regions was similar between females injected during either proestrus or estrus at 4, 7, 14, and 21 d after BrdU incorporation. The percentages of double-labeled cells were therefore collapsed across proestrus and estrus groups and are reported in the table above. The percentage of BrdU-labeled cells in the gcl and sgz that were immunoreactive for calbindin demonstrated a gradual but steady increase from 2.5% at 4 d to 68% at 21 d [p = 0.0003]. In contrast, the percentages of BrdU-labeled cells in the gcl and sgz that were immunoreactive for either TOAD-64 (∼60%) or GFAP (∼15%) did not change significantly over time in either group. Likewise, the percentages of double-labeled cells did not change in the hilus. In females injected during proestrus or estrus, no BrdU-labeled cells immunoreactive for calbindin or TOAD-64 were detected at any time point in the hilus, and the percentage of BrdU labeled cells in the hilus that were immunoreactive for GFAP was consistently <1.0%.